



(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/EP2021/084133

(22) International Filing Date:
03 December 2021 (03.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20211862.6 04 December 2020 (04.12.2020) EP
21158806.6 23 February 2021 (23.02.2021) EP
21163696.4 19 March 2021 (19.03.2021) EP
21172671.6 07 May 2021 (07.05.2021) EP
21177336.1 02 June 2021 (02.06.2021) EP
21205447.2 29 October 2021 (29.10.2021) EP

(71) Applicants: **MORPHOSYS AG** [DE/DE]; Semmelweisstr. 7, 82152 Planegg (DE). **INCYTE CORPORATION** [US/US]; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(72) Inventors: **FINGERLE-ROWSON, Günter**; Bozener Strasse 7, 82319 Starnberg (DE). **BRUGGER, Wol-**

fram; Buchhierlstraße 9, 81479 Munich (DE). **MANZKE, Oliver**; Incyte Biosciences International Sàrl, Rue Docteur-Yersin 10, 1110 Morges (CH). **SEGUY, Francis**; Incyte Biosciences International Sàrl, Rue Docteur-Yersin 10, 1110 Morges (CH).


(74) Agent: **SPILLER, Stephan** et al.; Morphosys AG, Semmelweisstr. 7, 82152 Planegg (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: ANTI-CD19 COMBINATION THERAPY

FIGURE 1: Trial design



(57) Abstract: The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and R-CHOP or an anti-CD19 antibody, lenalidomide, and R-CHOP for use in the treatment of diffuse large B cell lymphoma. The present disclosure is also directed to a therapeutic combination of an anti-CD19 antibody, lenalidomide, and rituximab for use in the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, or acute lymphoblastic leukemia.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*